Update on Discontinuation of Zoladex

On 1 May 2026, USANZ shared news from AstraZeneca about the discontinuation of ZOLADEX 3.6mg implant in Australia. This was to take effect from November 2026.

AstraZeneca has now shared an update on this decision, acknowledging the importance of maintaining continuity of care for patients.

For eligible patients without alternative treatment pathways, AstraZeneca will provide free access to the ZOLADEX 3.6 mg implant in Australia following its discontinuation in Australia from 1 November 2026. The access program will be initiated from 1 November 2026 for six months and reviewed approximately every six months.

AstraZeneca is working urgently to finalise details of this program. This includes working with the clinical community to identify treatment options available to meet the needs of patients. Information about the ZOLADEX Access Program will be provided to clinicians as soon as possible.

As previously advised, AstraZeneca has prepared a government regulatory and reimbursement application to expand the indication for the ZOLADEX® (goserelin) 10.8 mg implant to include breast cancer patients that are hormone receptor positive.

Please refer any questions to AstraZeneca’s Medical Information team.